Open AccessArticle
Patient-Derived Microtumors: How Can We Continue to Personalize Treatment for Ovarian Cancer Patients?
by
Emily O'Brien, Dhruva Dave, Abbie Kleckley, Fibiana Oladipo, Christopher M. Mayer, Rebecca Henderson, Blanca Vasquez, Elizabeth Lucas, Jeffrey A. Thomas, Rony Thomas, Raj Singh, Jingsong Chen, Michael D. Toboni, Charles A. Leath III and Rebecca C. Arend
Viewed by 664
Abstract
Background/Objectives: This pilot study investigates the feasibility of using patient-derived microtumors (PDMs) to assess chemotherapy response in epithelial ovarian cancer. Methods: Fresh tissue from 10 patients was used to develop PDMs, which were then tested against carboplatin/paclitaxel, carboplatin/docetaxel, and carboplatin/pegylated liposomal doxorubicin (PLD).
[...] Read more.
Background/Objectives: This pilot study investigates the feasibility of using patient-derived microtumors (PDMs) to assess chemotherapy response in epithelial ovarian cancer. Methods: Fresh tissue from 10 patients was used to develop PDMs, which were then tested against carboplatin/paclitaxel, carboplatin/docetaxel, and carboplatin/pegylated liposomal doxorubicin (PLD). Of the 10 PDMs, 3 were obtained from primary debulking surgery (PDS), and 7 were obtained at the time of interval debulking surgery following neoadjuvant chemotherapy. Results: When looking at PDMs derived from tissue collected at the time of PDS, we found that 100% of PDMs demonstrated a full response to carboplatin/PLD, while 30% showed a full response to all regimens, all of which were derived from high-grade serous carcinoma during PDS. The remaining PDMs showed moderate responses to carbo/taxol and carbo/doce. Conclusions: This study suggests that PDMs can be used to assess the efficacy of chemotherapy regimens, as a hypothesis-generating step toward future predictive validation.
Full article
►▼
Show Figures